Results 81 to 90 of about 34,080 (270)

UHPLC–MS/MS Method for the Simultaneous Quantification of 12 Antiretroviral Drugs in Human Plasma Using Dried Sample Spot Devices: Development, Validation, and Stability Evaluation

Pharmaceutics
Background/Objectives: In several contexts, Dried Sample Spot Devices (DSSDs) offer a convenient and safe alternative for sampling, storage, and shipment, allowing the transport and storage of biological samples at room temperature, reducing shipment ...
Sara Soloperto, Elisa Martina, Alice Palermiti, Elisa Barnini, Greta Sabbia, Gianluca Bianco, Martina Billi, Camilla Martino, Alessandra Manca, Marco Simiele, Jessica Cusato, Antonio D’Avolio, Amedeo De Nicolò   +12 more
doaj   +1 more source

Pharmacogenetics and personalized medicine

Saúde & Tecnologia, 2016
Pharmacogenetics aims to identify genetic differences between individuals that may influence the response to drug therapy, improving their effectiveness and safety. Associated with the pharmacogenetics emerges ‘personalized medicine’.
Miguel Brito
doaj   +1 more source

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz, Pimrapat Gebert, Jingwen Luo, Paraskevi Tassopoulou, Juliane Bolbrinker, Antonios Douros   +5 more
wiley   +1 more source

Characterization of NAT2 Using Long‐Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies

Clinical Pharmacology &Therapeutics, EarlyView.
The NAT2 pharmacogene is essential in drug metabolism, particularly for aromatic amines and hydrazines. Genetic variations in NAT2 categorize individuals as rapid, intermediate, or poor metabolizers based on their acetylation capacity to inform dosing guidelines.
Shobana John, Erin C. Boone, Byunggil Yoo, Laura B. Ramsey, Andrea Gaedigk   +4 more
wiley   +1 more source

PHARMACOGENETICS: ETHICAL ISSUES

, 2003
abstrac
Nuffield Council on Bioethics
core   +3 more sources

Biography as the Missing Variable in Drug Development: A Case for Bio‐Biographical Mechanistic Profiling

Clinical Pharmacology &Therapeutics, EarlyView.
Most clinical trial failures reflect unmeasured biological heterogeneity. Biography — chronic stress, adversity, trauma, and social isolation—is a neglected source of that heterogeneity, operating through the same molecular pathways drugs engage.
Ralph I. Horwitz
wiley   +1 more source

The Effects of Pharmacogenetics on Pharmacokinetics\ud of Artemisinin-Based Combinations in Malaria Patients [PDF]

, 2009
Malaria is a vector-borne infectious disease caused by protozoan parasites of the genus Plasmodium. If not treated appropriately, human P. falciparum malaria can quickly become life-threatening, leading to an estimated 900’000 annual deaths globally. Key
Hodel, Eva Maria
core  

A loss-of-function human ADAR variant activates innate immune response and promotes bowel inflammation

Nature Communications
Inflammatory bowel disease (IBD) arises from genetic-environmental interactions. Adenosine deaminases acting on RNA 1 (ADAR), an RNA-editing enzyme converting adenosine (A) to inosine (I), is essential for tissue homeostasis.
Pengfei Xu, Yue Xi, Jong-Won Kim, Min Zhang, Chen Gao, Yue Wang, Meishu Xu, Xingchen Wang, Songrong Ren, Da Yang, Qingde Wang, Wen Xie   +11 more
doaj   +1 more source

Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine

Background/Objectives: The clinical implementation of pharmacogenetics (PGx) remains limited, even for well-established drug–gene interactions. In addition to insufficient infrastructure and PGx education among healthcare professionals, there is ...
María Teresa Nieto-Sánchez, Alicia Torres-García, Emilio Fernández-Varón, Isabel Blancas, Rocío Morón, Xando Díaz-Villamarín, José Cabeza-Barrera, María Martínez-Pérez   +7 more
core   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source